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Lymphoid interstitial pneumonia (LIP) is a poorly understood lymphoproliferative disorder that can be
idiopathic or associated with different conditions. LIP is considered to be steroid responsive. However, its
response is mainly unpredictable with a high mortality rate. Here we describe a rare case of idiopathic
LIP that shows clinical improvement to Mycophenolate Mofetil after intolerable side effects of high-dose
steroids.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Lymphoid interstitial pneumonia (LIP) is a poorly understood
lymphoproliferative disorder originating from hyperplasia of
bronchus-associated lymphoid tissue (BALT). Peribronchiolar and
interstitial lymphocytes accumulate in response to various stimuli.
LIP is usually found in association with several diseases and condi-
tions, however some remain idiopathic. Up to 25% of LIP cases are
associated with Sjögrens Syndrome. Some studies suggest associa-
tions with HIV and EpsteineBarr virus. Although LIP has been
regarded as steroid responsive and mainly treated with oral corti-
costeroids, its response has been unpredictable. Approximately 33e
50%of patients diewithin 5 years of diagnosis, and approximately 5%
of cases of LIP transform to lymphoma.1 Previous reports have shown
successful treatment with Cyclophosphamide pulse therapy and
Rituximab in associationwith Sjögrens Syndrome.2,3 Another report
shows responsive treatment with Prednisone and Mycophenolate
Mofetil (MMF) in association with Systemic Lupus Erythematosus
(SLE).4 Here we describe a case of idiopathic LIP showing good
response to MMF, allowing for a rapid taper of Prednisone.2. Case report
A 35 year-old Guyanese female presented to our hospital with
progressive left-sided pleuritic chest pain, intermittent dry coughashi).
-NC-ND license.and exertional dyspnea. She denied history of fever, tuberculosis or
known exposure, asthma, seasonal allergy, gastroesophageal reﬂux
disorder, postnasal drip or smoking tobacco. She moved to New
York City from Guyana 10 years prior with no recent travel history
or sick contact. The patient used towork as a certiﬁed nurse aid and
owned a rabbit. She denied any history of muscle weakness, joint
pain, rash, photosensitivity, color changes in her digits, dysphagia,
dry eyes or dry mouth. Chest x-ray showed small inﬁltrates in the
left lung base. D-dimer was elevated and CT thorax showed mod-
erate interstitial and airspace opacities in lower lobes, atelectasis
and/or pneumonia with no evidence for pulmonary embolism. She
was diagnosed with community acquired pneumonia and dis-
charged home onMoxiﬂoxacin Hydrochloride. Three days later, the
patient returned to the ER with complaints of worsening shortness
of breath, left-sided chest pain and generalized macules. She was
given Methylprednisolone and Azithromycin to ﬁnish her course
for pneumonia and discharged home. Shewas followed for the next
several months in an outpatient setting. Therewas improvement in
the left-sided chest pain, however still present after 5 months.
Serial HRCT of thorax showed bilateral opacities, predominantly in
the lower lung zones with no signiﬁcant interval change. Therewas
no signiﬁcant mediastinal, hilar or axillary lymphadenopathy (Fig
2A). Pulmonary function testing was signiﬁcant for moderate
restrictive dysfunction with low diffusing capacity. CRP and ANA
titer levels were elevated; 10.5 mg/dL and 1:40 (speckled appear-
ance) respectively. P-ANCA [myeloperoxidase] and rheumatoid
factor levels were slightly elevated; 20 U/mL and 26 IU/mL
respectively. HIV, hepatitis B/C, quantiferon, anti-cyclic citrulli-
nated peptide, anti-ribonucleoprotein, anti-centromere, anti-Ro/La,
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tive. C3 and C4 levels were within normal range. Urinalysis was
negative for RBC, blood and protein. Bronchoscopy with right lower
lobe biopsy showed minute fragments of unremarkable bronchial
wall with no lung parenchyma identiﬁed. Cytology showed nega-
tive malignant cells with numerous benign bronchial cells, lym-
phocytes, neutrophils and macrophages. Bronchoalveolar lavage
showed no growth in mycobacterium and fungal cultures with no
pneumocystis on smear. After a couple weeks, she was admitted to
our hospital secondary to worsening dyspnea on exertion and left-
sided chest pain. Video-assisted thoracic surgery (VATS) was per-
formed for lung biopsy. Lung tissue showed no growth in myco-
bacterium and fungal cultures with no pneumocystis on smear. Left
upper and lower lung pathology suggested lymphoid (BALT) hy-
perplasia with acute and predominantly chronic ﬁbrous
pleuritis (Fig. 1). Methylprednisolone pulse therapy was initiated
followed by Prednisone 80 mg daily as an outpatient regimen. After
a month, the patient developed an acneiform rash on her face, a
cushingoid appearance, restlessness and anxiety. At that point,
MMF 1 g daily was initiated. Throughout the next 5 months, MMF
was increased to 2 g with a rapid taper of Prednisone to 5 mg daily.
There was complete resolution in the patient’s symptoms with
signiﬁcant clearing of sub-segmental opacities on serial CT (Fig. 2B).Fig. 1. Lymphoid hyperplasia with reactive germinal center formation; more diffuse on
left and more nodular on right. (A) H&E, 40 (B) H&E, 100.
Fig. 2. HRCT of thorax. (A) Bilateral opacities in the lower lung zones (B) signiﬁcant
clearing of sub-segmental opacities.Repeat labs included negative ANA and CRP levels; however p-
ANCA continued to stay in the same range until three months later
in which they were negative. At that point the patient was in
complete remission on MMF 2 g daily with Prednisone completely
tapered off. Repeat pulmonary function testing showed improve-
ment in total lung capacity and normal diffusing capacity.
3. Discussion
LIP is a poorly understood lymphoproliferative disorder with
unknown pathogenesis. It is associated with several diseases and
conditions including Sjögrens syndrome, HIV and EpsteineBarr
virus. Treatment regimens have not been well established.1 How-
ever, LIP is believed to respond to steroid therapy most of the time.
In our case, the patient was diagnosed with idiopathic LIP. She had
no signs of associated conditions, including Sjögrens syndrome or
HIV. Initial low ANA levels were attributed to the inﬂammatory
process in the lungs with no criteria meeting connective tissue
disease. Even though serial p-ANCA levels trended in the same
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vasculitis. After initial pulse therapy with Methylprednisolone fol-
lowed by a high-dose Prednisone regimen, the patient was not able
to tolerate the side effects. She developed an acneiform rash on her
face, a cushingoid appearance, restlessness and anxiety. By starting
the patient on MMF, a rapid taper of Prednisone was allowed with
complete remission.
MMF was originally approved by the FDA for prevention of
transplant rejection. It inhibits the synthesis of guanosine mono-
phosphate (GMP), preventing the proliferation of T and B lym-
phocytes. MMF has had an increase use in rheumatic diseases,
including maintaining remission in moderately severe SLE.5 Addi-
tionally, other reports have shown responsive treatment with
Prednisone and MMF in LIP associated with SLE and MMF alone in
connective tissue disease-associated interstitial lung disease.4,6
4. Conclusion
In summary, we report a case of idiopathic LIP. MMFwas started
secondary to intolerable side effects of high-dose Prednisone,
allowing for a rapid taper and resolution of symptoms. There was
improvement in radiologic ﬁndings on serial HRCT, pulmonary
function testing and clinical presentation. This case will further
support the previously mentioned report of LIP associated with
SLE.4 In cases of failed therapy with steroids or severe side effects,one may consider the use of MMF for further treatment. More
research will be needed for fostering treatment guidelines in cases
of LIP.Conﬂict of interest
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